EVOK - Evoke Pharma GAAP EPS of -$0.07 misses by $0.03 revenue of $0.42M misses by $0.12M
Evoke Pharma press release (NASDAQ:EVOK): Q1 GAAP EPS of -$0.07 misses by $0.03. Revenue of $0.42M (+366.7% Y/Y) misses by $0.12M. Existing cash and cash equivalents of $7.7M, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the second quarter of 2023.
For further details see:
Evoke Pharma GAAP EPS of -$0.07 misses by $0.03, revenue of $0.42M misses by $0.12M